Biofrontera AG

Biofrontera AG is a German biopharmaceutical company specializing in the development and sale of dermatological drugs and medical cosmetics. Founded in 1997 by Hermann Lübbert, it is headquartered in Leverkusen, Germany. The company is publicly traded, listed on the Frankfurt Stock Exchange (Prime Standard) and the US NASDAQ. As of 2026, Biofrontera AG has approximately 69 employees and a market capitalization of around $16.5 million, with a trailing 12-month revenue of $15.8 million.

Biofrontera AG's primary products include Ameluz®, a topical prescription drug used in photodynamic therapy (PDT) for certain superficial skin cancers and their precursors, such as actinic keratosis. This treatment is often combined with their proprietary red-light lamps, BF-RhodoLED® and BF-RhodoLED XL. The company also markets the dermocosmetics series Belixos® for damaged or diseased skin. Biofrontera distributes its products through its own sales organizations in Germany, Spain, and the UK, and via independent license partners in other regions.

Regarding patent litigation, Biofrontera AG primarily operates as a plaintiff, asserting its intellectual property rights. The company has two tracked cases, both as a plaintiff, against Sun Pharmaceutical Industries Inc. at the Patent Trial and Appeal Board (PTAB). These cases were initiated in April and August 2024. The plaintiff-only posture suggests Biofrontera AG actively defends or asserts its patent portfolio related to its pharmaceutical products.

Notable cases include Biofrontera AG v. Sun Pharmaceutical Industries Inc. (2024-04-30) and Biofrontera Pharma GMBH et al. v. Sun Pharmaceutical Industries Inc. (2024-08-21), both before the PTAB. These cases likely pertain to the company's core dermatological treatments, given their focus on pharmaceutical products. Biofrontera has also recently focused on obtaining US approval for Ameluz® for superficial basal cell carcinoma and acne, and new indications for actinic keratosis on areas beyond the face and scalp.